Oncept IL-2

RSS

feline interleukin-2 recombinant canarypox virus (vCP1338 virus)

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 24/04/2018

Authorisation details

Product details
Name
Oncept IL-2
Agency product number
EMEA/V/C/002562
Active substance
vCP1338 virus
International non-proprietary name (INN) or common name
feline interleukin-2 recombinant canarypox virus (vCP1338 virus)
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QL03AX
Publication details
Marketing-authorisation holder
Merial 
Revision
2
Date of issue of marketing authorisation valid throughout the European Union
03/05/2013
Contact address
Merial
29 avenue Tony Garnier
69007 Lyon
France

Product information

21/03/2018 Oncept IL-2 - EMEA/V/C/002562 - R/0006

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antineoplastic and immodulating agents

Therapeutic indication

Immunotherapy to be used in association with surgery and radiotherapy in cats with fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement, to reduce the risk of relapse and increase the time to relapse (local recurrence or metastasis).

Assessment history

How useful was this page?

Add your rating